[L-MTP-PE–a potential antineoplastic agent]

K Dzierzbicka ¹ , M Gozdowska , A M Kołodziejczyk

1. Katedra Chemii Organicznej, Politechniki Gdańskiej w Gdańsku.

Published:

GICID: 01.3001.0000.3131

Available language versions: en pl

Issue: Postepy Hig Med Dosw 1997; 51 (2)

Abstract

Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic lipophilic analogue of muramyl dipeptide, stimulates monocytes/macrophages to kill a variety of tumor cells in vitro and in vivo. Encapsulation of MTP-PE into multilamellar liposomes (L-MTP-PE) was specifically designed for in vivo targeting to macrophages by i.v. infusion and is the only form of the drug currently available for clinical trials (CGP 19835A Lipid). L-MTP-PE is presently undergoing clinical trials in patients with recurrent osteosarcoma and melanoma. L-MTP-PE combined with other anticancer agents may thus improve long-term cure rates of patients with this diseases.